ClinicalTrials.gg
Enrolling by invitationNCT06878976Updated Nov 6, 2026

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

A Phase 3 interventional study of Solriamfetol and Placebo in Binge-Eating Disorder, sponsored by Axsome Therapeutics, Inc.. Enrolling by invitation at 34 sites in United States. Open to participants aged 18 Years to 56 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 6, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 56 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Planned enrollment
16th of 112
236 · median 67
Started
2025
with 9 others
Phase 3
15 of 122
2 open now
Primary completion
2027-12
later than 17 of 27 live
Registered
112th of 122
by date

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 16th largest by planned enrollment of the 112 interventional ones that give a count, is one of 10 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 17 of the 27 other live ones, and was the 112th registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 56 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, multi-center, open-label and randomized withdrawal study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.

Read the detailed description

This study includes three segments: Open-Label (OL), Double-Blind Randomized Withdrawal (RW), and Open-Label Return (OLR). Eligible subjects will have completed the SOL-BED-301 (ENGAGE) study. All subjects will receive open-label solriamfetol for up to 52 weeks during the OL segment. Subjects who enter the RW segment will be randomized 1:1 to either continue solriamfetol or switch to placebo for up to 24 weeks of double-blind treatment, followed by a return to open-label solriamfetol in the OLR segment. The overall duration of study treatment is up to 77 weeks.

03

Conditions studied

  • Binge-Eating Disorder

Browse trials for

Keywords

  • Binge eating disorder
  • BED
  • Solriamfetol
  • Sunosi
  • Axsome
  • Non-stimulant therapy
  • Dopamine norepinephrine reuptake inhibitor
  • Trace amine-associated receptor 1 (TAAR1) agonist
04

Who can participate

Ages eligible
18 Years to 56 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the treatment period in Study SOL-BED-301.

Exclusion criteria

Exclusion Criteria:

  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Solriamfetol

    Experimental: Solriamfetol * Up to 52 weeks in the combined open-label and open-label return segments; * Up to 24 weeks in the double-blind randomized withdrawal segment

    Drug: Solriamfetol

  • Placebo comparator
    Placebo

    Up to 24 weeks in the double-blind randomized withdrawal segment

    Drug: Placebo

Interventions

  • Solriamfetol tablets, taken once daily

  • DrugPlacebo

    Placebo tablets, taken once daily

06

What researchers measure

Primary outcomes

  1. Time from randomization to relapse of binge eating in the RW segment

    Time frame: Up to 24 weeks

07

Study locations

34 sites
  • Clinical Research Site
    Encino, California 91316, United States
  • Clinical Research Site
    Long Beach, California 90806, United States
  • Clinical Research Site
    Santa Ana, California 92705, United States
  • Clinical Research Site
    Walnut Creek, California 94596, United States
  • Clinical Research Site
    West Covina, California 91790, United States
  • Clinical Research Site
    Colorado Springs, Colorado 80910, United States
  • Clinical Research Site
    Cromwell, Connecticut 06416, United States
  • Clinical Research Site
    Fort Myers, Florida 33912, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Lauderhill, Florida 33319, United States
  • Clinical Research Site
    Miami, Florida 33145, United States
  • Clinical Research Site
    Miami, Florida 33176, United States
  • Clinical Research Site
    Miami Lakes, Florida 33016, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Marietta, Georgia 30060, United States
  • Clinical Research Site
    Overland Park, Kansas 66212, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Saint Charles, Missouri 63304, United States
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
  • Clinical Research Site
    Mount Kisco, New York 10549, United States
  • Clinical Research Site
    New York, New York 10128, United States
  • Clinical Research Site
    Raleigh, North Carolina 27607, United States
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
  • Clinical Research Site
    Mason, Ohio 45040, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    North Canton, Ohio 44720, United States
  • Clinical Research Site
    Portland, Oregon 97210, United States
  • Clinical Research Site
    Allentown, Pennsylvania 18103, United States
  • Clinical Research Site
    North Charleston, South Carolina 29405, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    Austin, Texas 78731, United States
  • Clinical Research Site
    Austin, Texas 78737, United States
  • Clinical Research Site
    Dallas, Texas 75251, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Mar 17, 2025
StartActual
Feb 20, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Clinical Research Site · Colorado Springs, United States
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    1 site added
    Show site
    • Clinical Research Site · Colorado Springs, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06878976
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Feb 20, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion